Abstract:3042 Background: For advanced non-small cell lung cancer (NSCLC), liquid biopsy followed by targeted DNA sequencing is used in the clinical setting for driver-gene identification in circulating tumor DNA (ctDNA), tumor evolution and treatment monitoring. To understand the complexity and diversity of genetic alterations in advanced NSCLC, we examined the genetic landscape of late-stage NSCLC from an Asian population and its association with tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI) treatment. Methods: Plasma cell-free DNA (cfDNA) from 142 Asian patients with advanced NSCLC underwent real-world testing in a CAP-accredited and CLIA-certified central laboratory. We analyzed genetic alterations in cfDNA using an amplicon-based next-generation sequencing assay that covers 61 NSCLC related genes. 88 patients (62%) had received one or more lines of treatment. A similar cohort from Caucasian NSCLC was used for comparison (Blakely et al. Nat Genet 2017). Systematic co-mutation analysis, functional annotation and pathway enrichment analysis were performed. Results: The top 10 mutated genes in the Asian cohort were EGFR (66.2%), TP53 (48.6%), KRAS (11.3%), BRCA2 (7%), CTNNB1 (6.3%), PIK3CA (6.3%), SMAD4 (5.6%), BRCA1 (4.9%), MET (3.5%) and RB1 (3.5%). EGFR mutations occurred at hotspots in exons 18 – 21, with exon19 deletion, L858R, T790M, C797S, and G719A being the top-ranking alleles, similar to the Caucasian NSCLC cohort. Concurrent KRAS and EGFR mutations were higher in Asian cohort (8.5%) than in Caucasian cohort (0.56%). A rare PD-L1 structural variant (1.1%), reported to be related to immune evasion in other cancers (Kataoka et al. Nature 2016), was detected in the EGFR-mutated subgroup. Within the first line TKI-treated group, responders (CR+PR) harbored more alterations than non-responders (p < 0.017). Among ICI-treated NSCLC patients (anti-PD-1/PD-L1 mono- or polytherapy), responders from 1st line or 2nd line ICI treatment harbored fewer mutations than non-responders, but the distribution of mutational allele frequency (MAF) in responders was shifted to the right (more clonal than subclonal mutations). Functional annotation suggests that concurrent mutated genes and copy number alterations in advanced EGFR-mutant NSCLC were enriched in cell cycle, DNA repair, PI3K-AKT signaling pathways. Conclusions: We characterized the ctDNA-derived genetic landscape of advanced NSCLC from an Asian population and dissected mutated genes with the outcome of TKI or ICI treatment. We also report a rare PD-L1 structural variant in the EGFR mutated subgroup, which could be associated with immune evasion. Our analyses support the occurrence of clonal and subclonal driver co-alterations in EGFR-driven NSCLC, underlining the clinical utility of ctDNA detection for NSCLC diagnosis and treatment selection.

MA16.06 EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctdna) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

P2.15-33 Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens after Panel Testing by NGS?

Detection and Dynamic Changes of Egfr Mutations from Circulating Tumor Dna As A Predictor of Survival Outcomes in Nsclc Patients Treated with First-Line Intercalated Erlotinib and Chemotherapy

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Clonal Dominance of EGFR and Efficacy of EGFR-tyrosine Kinase Inhibitors (Egfr-Tkis) in NSCLC.

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Clinical Potential Of Ctdna-Based Tmb In Small Cell Lung Cancer Recieving Chemoradiotherapy.

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Impact of Plasma EGFR Mutation Fractions on Response to First Generation Tyrosine-Kinase Inhibitor in Treatment of Naïve Non-Small Cell Lung Cancer Patients

P1.01-035 A Next Generation Sequencing and Characteristics Based Model for Predict Clinical Benefits of Advanced NSCLC Patients

Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from Asian population.

Tumor Mutation Burden Correlates with Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

P3.02b-098 Plasma T790M Mutation Associates with Extensive Progression in Non-small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors: Topic: EGFR RES

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

P2.01-116 the Potential of Assessing Blood Tumor Mutation Burden (btmb) Using a Large Panel